Where the Money Is 08.27.2014

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 27 August 2014

⏱️ 16 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In today’s healthcare-focused episode of Where The Money Is, Motley Fool analysts David Williamson and Michael Douglass talk about an exciting new study on medical marijuana and a big biotech buyout.

Transcript

Click on a timestamp to play from that location

0:00.0	A biotech buyout, a breakthrough cancer drug on the way, and the possible solution to America's
0:06.1	painkiller problem, because this is where the money is.
0:11.8	Hi Fools, welcome to the Wednesday Health Care Edition of Where the Money is.
0:15.8	I'm David Williamson and I'm joined by my fellow health care analyst in arms, Michael
0:19.9	Douglas.
0:20.9	Michael, how are you doing this week?
0:21.9	Fantastic. Doing week? Fantastic.
0:22.8	Doing well?
0:23.8	Yeah.
0:24.8	We have a jam-packed show, as always.
0:26.5	We have a biotech buyout that we should be covering.
0:29.5	Sure, let's start with that.
0:30.6	So Valiant and Aller.
0:32.1	Oh, no.
0:33.0	What for once we're not going to talk about that.
0:35.0	I'd prefer not to you.
0:36.0	Although they are going to have a shareholder meeting
0:38.0	which is what the hedge fund Pershing Square
0:41.0	lived by Bill Ackman and Valiant have been arguing that
0:44.4	Allegan needs to have one because they think the shareholders will side with
0:48.0	them and they'll get some board seats and make this deal happen but we're not
0:51.0	really going to cover that today because I feel like we've just
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.